Search 

UB is a premier, research-intensive public university and a member of the Association of American Universities. As the largest, most comprehensive institution in the 64-campus State University of New York system, our research, creative activity and people positively impact the world. 

As a SUNY Distinguished Professor and Associate Director of the New York State Center of Excellence in Bioinformatics and Life Sciences, Dr. Morse has extensive experience in coordinating and governing multidisciplinary research efforts involving health information technology to improve patient safety. Dr. Morse also directs the Empire State Patient Safety Assurance Network, an AHRQ-designated, federally certified Patient Safety Organization and has led the UB 2020 effort to develop a model for statewide medication management programs in partnership with the NYS Department of Health Patient Safety Center. Dr. Morse has also worked with UB to establish the ESPSAN as a component of the UB 2020 planning process, a program that includes the School of Pharmacy and Pharmaceutical Sciences, Nursing, Medicine and Public Health. He also developed the UB Pharmacotherapy Information Center (PIC) and has led an effort to develop model medication management programs in Western New York and established the regional HIV Adherence-Pharmacology Program. Dr. Morse is also Co-Director of the UNYTE Translational Research Network of the University of Rochester CTSI, regional network composed of 18 academic and research institutions. In addition, Dr. Morse is the Director of the Translational Pharmacology Research Core in the New York State Center of Excellence in Bioinformatics and Life Sciences. Dr. Morse also holds appointments as a Professor in the Department of Pharmacy Practice, and Research Professor of Medicine and Pediatrics, at the University at Buffalo. Dr. Morse was previously the Associate Dean of Clinical and Translational Research in the School of Pharmacy and Pharmaceutical Sciences at the University at Buffalo.

UrgoTouch is the first preventive laser which significantly improves the post-operative scar aesthetic and functional results.

Today, there is no good way to prevent unsightly scars: there should be a solution that would give more control over the scar aesthetic and functional results.

1) Aesthetics surgeons and any surgeon looking to deliver a functional and aesthetic scar after surgery

2) Aesthetics dermatologists for small operations in their office

1) High level of research, development and clinical performance

2) Restoring patients former quality of life

3) Innnovative breakthrough for a large patient demand

4) Bring Urgo medical grade expertise in skin and healing to the aesthetic market

VentriNova is a regenerative medicine company focused on reversing cardiac damage by activation of intrinsic repair pathways to generate de novo heart muscle cells. VentriNova’s first generation product is a gene therapy that delivers a critical mitotic regulator to diseased heart tissue to stimulate proliferation of cardiac muscle cells.

• No technology on the market or in clinical development, including stem cell-based technologies and other regenerative medicine applications, has the ability to grow new heart muscle cells in the diseased heart.

• VentriNova’s pioneering science and technology is centered on development of biologic and small molecule regulators of the cyclin A2 gene – the key switch mediating heart cell division.

• VentriNova’s technology demonstrated in both small and large animals the ability to control the modulation (increased gene expression) of the cyclin A2 gene, therefore stimulating endogenous growth of new myocytes (heart muscle cells).

• VentriNova’s VN-100 technology is the conductor that orchestrates existing human heart
  cells to divide and regenerate themselves – a cellular function that is silenced in early human development.

The VIE Program is a hassle-free HR package offered by the French government which allows your company to recruit highly skilled young professionals from Europe.  It is entirely flexible and comes with many financial advantages, which explains why the program is so successful. There are currently 8200 VIEs assigned in 1800 companies worldwide and the US is the #1 destination with more than 1000 VIEs currently assigned.

Visterra is a biotechnology company that uses its proprietary Hierotope™ Platform to identify unique disease targets and design and engineer effective therapeutics. The company’s technology is powered by computational tools and techniques, the core of which is Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. This ideal epitope, or hierotope, becomes the target against which the company designs a novel therapeutic to effectively and durably combat the disease. 

The company is currently focused on therapeutics for infectious diseases, and its lead product candidate, VIS410, is a broad spectrum human monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza. The company’s second product candidate, VIS513, is a human monoclonal antibody for the treatment of dengue that has been shown to broadly neutralize all four dengue virus serotypes.

Our companion software embed patient-doctor connectivity and clinical intelligence into existing therapeutics or medical devices. We rely on our ISO-certified processes, medical algorithms and clinical studies of our software to create solutions that ensure safety and efficacy for our users.

People suffering from chronic diseases often find themselves lost in their treatment protocols once they leave the doctor's office. They lack a way of communicating with their health care teams and the support to take the appropriate dose of medication, manage symptoms and control side effects.

Pharmaceutical companies / Health care payers / Medical device manufacturers

Convergence of medical and technological solutions / Results backed by clinical trials / Quality and regulatory expertise / Extensive track record